Kevin Balthaser - Jan 1, 2023 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, as Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/6/2023, 03:31 PM
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRS Common Stock 700 Jan 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRS Employee Stock Option (Right to Buy) Jan 1, 2023 Common Stock 11.2K $27.54 Direct F1
holding ACRS Employee Stock Option (Right to Buy) Jan 1, 2023 Common Stock 2.1K $22.09 Direct F1
holding ACRS Employee Stock Option (Right to Buy) Jan 1, 2023 Common Stock 15.5K $24.06 Direct F2
holding ACRS Employee Stock Option (Right to Buy) Jan 1, 2023 Common Stock 33.4K $14.94 Direct F3
holding ACRS Restricted Stock Units Jan 1, 2023 Common Stock 1.48K Direct F4, F5
holding ACRS Restricted Stock Units Jan 1, 2023 Common Stock 3K Direct F5, F6
holding ACRS Restricted Stock Units Jan 1, 2023 Common Stock 2K Direct F5, F7
holding ACRS Restricted Stock Units Jan 1, 2023 Common Stock 3.3K Direct F5, F8
holding ACRS Restricted Stock Units Jan 1, 2023 Common Stock 9.5K Direct F5, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option are fully vested. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F2 The option vests over a period of four years. 25% of the shares are currently vested with the remaining 75% vesting annually on March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F3 The option vests over a period of four years. 25% of the shares will vest on March 1, 2023, with the remaining 75% vesting annually thereafter on March 1, 2024, March 1, 2025 and March 1, 2026, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F4 The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F5 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F6 The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F7 The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F8 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F9 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney